Reduce uncertainty in market access

Today 90% of clinical investigations fail due to poor trial design, inability to access relevant information, difficulty in interpreting the collected data or a lack of representativity of the results. That is why a real global change of the R&D paradigm is needed to stop the decline in both the efficiency and the productivity of drug development worldwide, especially during the COVID19 pandemic.

To learn more how Novadiscovery's Modeling & Simulation can help reduce this uncertainty, download our white paper

Download our White Paper


Content of the case study


Uncertainty at the time of market access 

From bench top to patients, the life of a new medical product is a continuous accrual of data aimed at answering the question: “Can the activity observed on a Petri dish result in improved health benefits for patients (and the population)?”.This data accumulation process is punctuated by decision-making taken in uncertain settings. One of the most challenging decisions because of this uncertainty is market access.


The fundamentals of the NOVA Modeling & Simulation solution

The three components of NOVA’s solution are: (i) the disease model, which is a mathematical representation of the disease; (ii) the drug model, which is a mathematical representation of the behavior of the compound in the body, from administration to its target(s) in the disease model; (iii) the virtual population (VP), which is a collection of virtual individuals defined by a set of values of model parameters.


A few illustrative examples for market access applications

M&S can help by eliminating most of the uncertainty that makes market access difficult.Illustration examples of Modeling & Simulation applied to market access: (i) treatment of reperfusion injury; (ii) prevention of lung graft rejection; (iii) interaction between a anti HBV NMP and established treatments; (iv) non persistent efficacy in chronic treatment.